Jeffrey B Kopp

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1941498/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Urine Single-Cell RNA Sequencing in Focal Segmental Glomerulosclerosis Reveals Inflammatory Signatures. Kidney International Reports, 2022, 7, 289-304.	0.8	21
2	Alpha Globin Gene Copy Number Is Associated with Prevalent Chronic Kidney Disease and Incident End-Stage Kidney Disease among Black Americans. Journal of the American Society of Nephrology: JASN, 2022, 33, 213-224.	6.1	8
3	<i>APOL1</i> Risk Variants Associated with Serum Albumin in a Population-Based Cohort Study. American Journal of Nephrology, 2022, 53, 182-190.	3.1	0
4	Aryl Hydrocarbon Receptor Mechanisms Affecting Chronic Kidney Disease. Frontiers in Pharmacology, 2022, 13, 782199.	3.5	13
5	The evolving story of apolipoprotein L1 nephropathy: the end of the beginning. Nature Reviews Nephrology, 2022, 18, 307-320.	9.6	38
6	Associations between APOL1 genetic variants and blood pressure in African American mothers and children from a U.S. pregnancy cohort: Modification by air pollution exposures. Environmental Research, 2022, 212, 113186.	7.5	0
7	Antisense oligonucleotides ameliorate kidney dysfunction in podocyte-specific APOL1 risk variant mice. Molecular Therapy, 2022, 30, 2491-2504.	8.2	4
8	Genetics in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2022, 101, 1126-1141.	5.2	46
9	Susceptibility to kidney fibrosis in mice is associated with early growth response-2 protein and tissue inhibitor of metalloproteinase-1 expression. Kidney International, 2022, 102, 337-354.	5.2	10
10	PodoCount: A Robust, Fully Automated, Whole-Slide Podocyte Quantification Tool. Kidney International Reports, 2022, 7, 1377-1392.	0.8	7
11	Impact of APOL1 kidney risk variants on glomerular transcriptomes. Kidney International, 2022, 102, 16-19.	5.2	0
12	Etiology of Persistent Microalbuminuria in Nigeria (P_MICRO study): protocol and study design. BMC Infectious Diseases, 2022, 22, .	2.9	0
13	APOL1 risk variants affect podocyte lipid homeostasis and energy production in focal segmental glomerulosclerosis. Human Molecular Genetics, 2021, 30, 182-197.	2.9	27
14	Proteinuria Reduction and Kidney Survival in Focal Segmental Glomerulosclerosis. American Journal of Kidney Diseases, 2021, 77, 216-225.	1.9	23
15	APOL1 variant alleles associate with reduced risk for opportunistic infections in HIV infection. Communications Biology, 2021, 4, 284.	4.4	4
16	APOL1 genotype-associated morphologic changes among patients with focal segmental glomerulosclerosis. Pediatric Nephrology, 2021, 36, 2747-2757.	1.7	3
17	PD-1 immunobiology in glomerulonephritis and renal cell carcinoma. BMC Nephrology, 2021, 22, 80.	1.8	17
18	Diagnosis, Education, and Care of Patients with APOL1-Associated Nephropathy: A Delphi Consensus and Systematic Review. Journal of the American Society of Nephrology: JASN, 2021, 32, 1765-1778.	6.1	13

#	Article	IF	CITATIONS
19	Severity modeling of propionic acidemia using clinical and laboratory biomarkers. Genetics in Medicine, 2021, 23, 1534-1542.	2.4	13
20	Joint Associations of Maternal-Fetal APOL1 Genotypes and Maternal Country of Origin With Preeclampsia Risk. American Journal of Kidney Diseases, 2021, 77, 879-888.e1.	1.9	20
21	Racial-Ethnic Differences in Health-Related Quality of Life among Adults and Children with Glomerular Disease. Glomerular Diseases, 2021, 1, 105-117.	1.0	6
22	APOL1 at 10 years: progress and next steps. Kidney International, 2021, 99, 1296-1302.	5.2	14
23	<i>APOL1</i> Genetic Variants Are Associated With Increased Risk of Coronary Atherosclerotic Plaque Rupture in the Black Population. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 2201-2214.	2.4	8
24	Apolipoprotein-1 risk variants and associated kidney phenotypes in an adult HIV cohort in Nigeria. Kidney International, 2021, 100, 146-154.	5.2	16
25	Association of Sickle Cell Trait With Incidence of Coronary Heart Disease Among African American Individuals. JAMA Network Open, 2021, 4, e2030435.	5.9	5
26	Introduction: Obesity and the kidney. Seminars in Nephrology, 2021, 41, 295.	1.6	0
27	Podocytopathy in Obesity: Challenges of Living Large. Seminars in Nephrology, 2021, 41, 307-317.	1.6	2
28	The key role of NLRP3 and STING in APOL1-associated podocytopathy. Journal of Clinical Investigation, 2021, 131, .	8.2	66
29	Lessons From APOL1 Animal Models. Frontiers in Medicine, 2021, 8, 762901.	2.6	4
30	Glomerular Kidney Diseases in the Single-Cell Era. Frontiers in Medicine, 2021, 8, 761996.	2.6	4
31	Observations from the emergency management of dialysis patients evacuated from the US Virgin Islands to Puerto Rico following hurricane Irma. BMC Health Services Research, 2021, 21, 1239.	2.2	3
32	circHIPK3 Exacerbates Folic Acid-Induced Renal Tubulointerstitial Fibrosis by Sponging miR-30a. Frontiers in Physiology, 2021, 12, 715567.	2.8	11
33	APOL1 Nephropathy Risk Alleles and Mortality in African American Adults: A Cohort Study. American Journal of Kidney Diseases, 2020, 75, 54-60.	1.9	7
34	Human Immunodeficiency Virus Infection and Chronic Kidney Disease. , 2020, , 849-861.		1
35	miR-150 inhibitor ameliorates adriamycin-induced focal segmental glomerulosclerosis. Biochemical and Biophysical Research Communications, 2020, 522, 618-625.	2.1	12
36	Longitudinal Changes in Health-Related Quality of Life in Primary Glomerular Disease: Results From the CureCN Study. Kidney International Reports, 2020, 5, 1679-1689.	0.8	17

#	Article	IF	CITATIONS
37	CircZNF609 is involved in the pathogenesis of focal segmental glomerulosclerosis by sponging miR-615-5p. Biochemical and Biophysical Research Communications, 2020, 531, 341-349.	2.1	17
38	Macrophage polarization in innate immune responses contributing to pathogenesis of chronic kidney disease. BMC Nephrology, 2020, 21, 270.	1.8	63
39	miR-150-Based RNA Interference Attenuates Tubulointerstitial Fibrosis through the SOCS1/JAK/STAT Pathway InÂVivo and InÂVitro. Molecular Therapy - Nucleic Acids, 2020, 22, 871-884.	5.1	33
40	Podocytopathies. Nature Reviews Disease Primers, 2020, 6, 68.	30.5	237
41	APOL1 renal risk variants exacerbate podocyte injury by increasing inflammatory stress. BMC Nephrology, 2020, 21, 371.	1.8	21
42	APOL1, Acidity, and ATP: Affecting Mitochondrial Function. American Journal of Nephrology, 2020, 51, 693-694.	3.1	0
43	Improving Care for Patients after Hospitalization with AKI. Journal of the American Society of Nephrology: JASN, 2020, 31, 2237-2241.	6.1	24
44	The longitudinal relationship between patient-reported outcomes and clinical characteristics among patients with focal segmental glomerulosclerosis in the Nephrotic Syndrome Study Network. CKJ: Clinical Kidney Journal, 2020, 13, 597-606.	2.9	14
45	COVID-19 Usurps Host Regulatory Networks. Frontiers in Pharmacology, 2020, 11, 1278.	3.5	27
46	COVID-19–Associated Collapsing Glomerulopathy: An Emerging Entity. Kidney International Reports, 2020, 5, 759-761.	0.8	96
47	Genetic Testing for APOL1 Genetic Variants in Clinical Practice. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 126-128.	4.5	17
48	Launching APOLLO: TheÂRole of APOL1 Genetic Variants in Live- and Deceased-Donor Kidney Transplantation. Kidney International Reports, 2020, 5, 252-254.	0.8	3
49	Persistent Disease Activity in Patients With Long-Standing Glomerular Disease. Kidney International Reports, 2020, 5, 860-871.	0.8	2
50	Interferon lambda promotes immune dysregulation and tissue inflammation in TLR7-induced lupus. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 5409-5419.	7.1	81
51	<p>Podocyte Density and Albuminuria in Aging Diabetic Ins2± Mice with or Without Adenosine A1 Receptor Signaling</p> . International Journal of Nephrology and Renovascular Disease, 2020, Volume 13, 19-26.	1.8	1
52	Elevated Plasma Free Sialic Acid Levels in Individuals with Reduced Glomerular Filtration Rates. Kidney360, 2020, 1, 957-961.	2.1	2
53	Chronic kidney disease in propionic acidemia. Genetics in Medicine, 2019, 21, 2830-2835.	2.4	27
54	APOL1 Nephropathy Risk Alleles and Risk of Sepsis in Blacks. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 1733-1740.	4.5	20

#	Article	IF	CITATIONS
55	Rationale and Design for a Phase 1 Study of N-Acetylmannosamine for Primary Glomerular Diseases. Kidney International Reports, 2019, 4, 1454-1462.	0.8	8
56	Impact of APOL1 Genetic Variants on HIV-1 Infection and Disease Progression. Frontiers in Immunology, 2019, 10, 53.	4.8	13
57	Optimal management of HIV- positiveÂadults at risk for kidney disease in Nigeria (Renal Risk Reduction) Tj ETQq1	. 1.0,7843 1.6	314 rgBT /O
58	Renal Failure Patients in Disasters. Disaster Medicine and Public Health Preparedness, 2019, 13, 782-790.	1.3	10
59	APOL1 renal risk variants promote cholesterol accumulation in tissues and cultured macrophages from APOL1 transgenic mice. PLoS ONE, 2019, 14, e0211559.	2.5	39
60	Gut microbiome-derived phenyl sulfate contributes to albuminuria in diabetic kidney disease. Nature Communications, 2019, 10, 1835.	12.8	173
61	Survival Advantage of African American Dialysis Patients with End-Stage Renal Disease Causes Related to APOL1. CardioRenal Medicine, 2019, 9, 212-221.	1.9	8
62	Health-related quality of life in glomerular disease. Kidney International, 2019, 95, 1209-1224.	5.2	38
63	Open-Label Clinical Trials of Oral Pulse Dexamethasone for Adults with Idiopathic Nephrotic Syndrome. American Journal of Nephrology, 2019, 49, 377-385.	3.1	3
64	APOL1 Kidney Risk Variants and Cardiovascular Disease: An Individual Participant Data Meta-Analysis. Journal of the American Society of Nephrology: JASN, 2019, 30, 2027-2036.	6.1	26
65	LNA-anti-miR-150 ameliorated kidney injury of lupus nephritis by inhibiting renal fibrosis and macrophage infiltration. Arthritis Research and Therapy, 2019, 21, 276.	3.5	35
66	One Actor, Many Roles: Histopathologies Associated With APOL1 Genetic Variants. Advances in Anatomic Pathology, 2019, 26, 215-219.	4.3	5
67	Apolipoprotein L1 Testing in African Americans: Involving the Community in Policy Discussions. American Journal of Nephrology, 2019, 50, 303-311.	3.1	22
68	CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular Disease. American Journal of Kidney Diseases, 2019, 73, 218-229.	1.9	68
69	c-Src is in the effector pathway linking uPAR and podocyte injury. Journal of Clinical Investigation, 2019, 129, 1827-1829.	8.2	10
70	Alpha Globin Gene Copy Number Is Associated with Kidney Disease Among Black Individuals. Blood, 2019, 134, 2248-2248.	1.4	0
71	Global glomerulosclerosis in primary nephrotic syndrome: including age as a variable to predict renal outcomes. Kidney International, 2018, 93, 1043-1044.	5.2	7
72	Association of Sickle Cell Trait With Ischemic Stroke Among African Americans. JAMA Neurology, 2018, 75, 802.	9.0	25

#	Article	IF	CITATIONS
73	Kidney Diseases Associated with Human Immunodeficiency Virus Infection. New England Journal of Medicine, 2018, 378, 1654-1656.	27.0	6
74	Genetic Testing in Clinical Settings. American Journal of Kidney Diseases, 2018, 72, 569-581.	1.9	33
75	Apolipoprotein L1 nephropathies. Current Opinion in Nephrology and Hypertension, 2018, 27, 153-158.	2.0	4
76	APOL1 Genotype and Renal Function of Black Living Donors. Journal of the American Society of Nephrology: JASN, 2018, 29, 1309-1316.	6.1	111
77	Banff Classification of Polyomavirus Nephropathy: A New Tool for Research and Clinical Practice. Journal of the American Society of Nephrology: JASN, 2018, 29, 354-355.	6.1	4
78	FXR/TGR5 Dual Agonist Prevents Progression of Nephropathy in Diabetes and Obesity. Journal of the American Society of Nephrology: JASN, 2018, 29, 118-137.	6.1	133
79	APOL1 Risk Variants Independently Associated With Early Cardiovascular Disease Death. Kidney International Reports, 2018, 3, 89-98.	0.8	14
80	Randomized Clinical Trial Design to Assess Abatacept in Resistant Nephrotic Syndrome. Kidney International Reports, 2018, 3, 115-121.	0.8	21
81	APOL1 nephropathy risk variants do not associate with subclinical atherosclerosis or left ventricular mass in middle-aged black adults. Kidney International, 2018, 93, 727-732.	5.2	18
82	Opposing Roles of Dendritic Cell Subsets in Experimental GN. Journal of the American Society of Nephrology: JASN, 2018, 29, 138-154.	6.1	65
83	Whole Exome Sequencing of Patients with Steroid-Resistant Nephrotic Syndrome. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 53-62.	4.5	170
84	Expanding the spectrum of APOL1-related renal disease: deÂnovo collapsing glomerulopathy following kidney transplant. Kidney International, 2018, 94, 1048-1050.	5.2	4
85	APOL1 risk allele RNA contributes to renal toxicity by activating protein kinase R. Communications Biology, 2018, 1, 188.	4.4	59
86	APOL1Nephropathy Risk Variants and Incident Cardiovascular Disease Events in Community-Dwelling Black Adults. Circulation Genomic and Precision Medicine, 2018, 11, e002098.	3.6	26
87	APOL1–miR-193 Axis as a Bifunctional Regulator of the Glomerular Parietal Epithelium. American Journal of Pathology, 2018, 188, 2461-2463.	3.8	4
88	APOL1-Associated Nephropathy: A Key Contributor to Racial Disparities in CKD. American Journal of Kidney Diseases, 2018, 72, S8-S16.	1.9	113
89	NPHS2 V260E Is a Frequent Cause of Steroid-Resistant Nephrotic Syndrome in Black South African Children. Kidney International Reports, 2018, 3, 1354-1362.	0.8	16
90	Clinical Characteristics and Treatment Patterns of Children and Adults With IgA Nephropathy or IgA Vasculitis: Findings From the CureGN Study. Kidney International Reports, 2018, 3, 1373-1384.	0.8	39

#	Article	IF	CITATIONS
91	Fetal—Not Maternal—APOL1 Genotype Associated with Risk for Preeclampsia in Those with African Ancestry. American Journal of Human Genetics, 2018, 103, 367-376.	6.2	49
92	Association of <i>APOL1</i> With Heart Failure With Preserved Ejection Fraction in Postmenopausal African American Women. JAMA Cardiology, 2018, 3, 712.	6.1	17
93	Genetics, Genomics, and Precision Medicine in End-Stage Kidney Disease. Seminars in Nephrology, 2018, 38, 317-324.	1.6	12
94	An eQTL Landscape of Kidney Tissue in Human Nephrotic Syndrome. American Journal of Human Genetics, 2018, 103, 232-244.	6.2	147
95	ApoL1 renal risk variants induce aberrant THP-1 monocyte differentiation and increase eicosanoid production via enhanced expression of cyclooxygenase-2. American Journal of Physiology - Renal Physiology, 2018, 315, F140-F150.	2.7	12
96	<i>APOL1</i> -associated glomerular disease among African-American children: a collaboration of the Chronic Kidney Disease in Children (CKiD) and Nephrotic Syndrome Study Network (NEPTUNE) cohorts. Nephrology Dialysis Transplantation, 2017, 32, gfw061.	0.7	60
97	Transgenic expression of human APOL1 risk variants in podocytes induces kidney disease in mice. Nature Medicine, 2017, 23, 429-438.	30.7	282
98	SGLT2 Protein Expression Is Increased in Human Diabetic Nephropathy. Journal of Biological Chemistry, 2017, 292, 5335-5348.	3.4	231
99	Sickle Cell Trait and the Risk of ESRD in Blacks. Journal of the American Society of Nephrology: JASN, 2017, 28, 2180-2187.	6.1	79
100	Focal Segmental Glomerulosclerosis. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 502-517.	4.5	359
101	APOL1 genetic variants are not associated with longitudinal blood pressure in young black adults. Kidney International, 2017, 92, 964-971.	5.2	17
102	Therapeutics for APOL1 nephropathies: putting out the fire in the podocyte. Nephrology Dialysis Transplantation, 2017, 32, i65-i70.	0.7	27
103	Extracellular microRNA signature in chronic kidney disease. American Journal of Physiology - Renal Physiology, 2017, 312, F982-F991.	2.7	46
104	Absence of APOL1 risk alleles in a remote living Australian Aboriginal group with high rates of CKD, hypertension, diabetes, and cardiovascular disease. Kidney International, 2017, 91, 990.	5.2	5
105	APOL1 Renal Risk Variants: Fertile Soil for HIV-Associated Nephropathy. Seminars in Nephrology, 2017, 37, 514-519.	1.6	28
106	HIV-1 viral protein R (Vpr) induces fatty liver in mice via LXRα and PPARα dysregulation: implications for HIV-specific pathogenesis of NAFLD. Scientific Reports, 2017, 7, 13362.	3.3	27
107	Chronic Kidney Disease in the Aging Human Immunodeficiency Virus–Infected Population. Journal of Infectious Diseases, 2017, 216, 619-621	4.0	9
108	Kidney Diseases Associated with Human Immunodeficiency Virus Infection. New England Journal of Medicine, 2017, 377, 2363-2374.	27.0	72

#	Article	IF	CITATIONS
109	A tripartite complex of suPAR, APOL1 risk variants and αvβ3 integrin on podocytes mediates chronic kidney disease. Nature Medicine, 2017, 23, 945-953.	30.7	176
110	Effect of Antiretroviral Therapy on Bone and Renal Health in Young Adults Infected With HIV in Early Life. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 2896-2904.	3.6	16
111	Redefined clinical features and diagnostic criteria in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. JCI Insight, 2016, 1, .	5.0	219
112	Renal and Cardiovascular Morbidities Associated with APOL1 Status among African-American and Non-African-American Children with Focal Segmental Glomerulosclerosis. Frontiers in Pediatrics, 2016, 4, 122.	1.9	29
113	Brief Report: APOL1 Renal Risk Variants Are Associated With Chronic Kidney Disease in Children and Youth With Perinatal HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 73, 63-68.	2.1	30
114	Intravital and Kidney Slice Imaging of Podocyte Membrane Dynamics. Journal of the American Society of Nephrology: JASN, 2016, 27, 3285-3290.	6.1	50
115	Combined Effects of GSTM1 Null Allele and APOL1 Renal Risk Alleles in CKD Progression in the African American Study of Kidney Disease and Hypertension Trial. Journal of the American Society of Nephrology: JASN, 2016, 27, 3140-3152.	6.1	38
116	Tenofovir Alafenamide as Part of a Salvage Regimen in a Patient with Multi-Drug Resistant HIV and Tenofovir-DF-Associated Renal Tubulopathy. Antiviral Therapy, 2016, 21, 553-558.	1.0	10
117	APOL1 Risk Alleles Are Associated With More Severe Arteriosclerosis in Renal Resistance Vessels With Aging and Hypertension. Kidney International Reports, 2016, 1, 10-23.	0.8	19
118	Complete Remission in the Nephrotic Syndrome Study Network. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 81-89.	4.5	53
119	Association of APOL1 Genotype with Renal Histology among Black HIV-Positive Patients Undergoing Kidney Biopsy. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 262-270.	4.5	27
120	APOL1 Genotype and Race Differences in Incident Albuminuria and Renal Function Decline. Journal of the American Society of Nephrology: JASN, 2016, 27, 887-893.	6.1	115
121	G Protein-Coupled Bile Acid Receptor TGR5 Activation Inhibits Kidney Disease in Obesity and Diabetes. Journal of the American Society of Nephrology: JASN, 2016, 27, 1362-1378.	6.1	140
122	Integrative Genomics Identifies Novel Associations with APOL1 Risk Genotypes in Black NEPTUNE Subjects. Journal of the American Society of Nephrology: JASN, 2016, 27, 814-823.	6.1	110
123	A role for genetic susceptibility in sporadic focal segmental glomerulosclerosis. Journal of Clinical Investigation, 2016, 126, 1067-1078.	8.2	41
124	Association of Sickle Cell Trait with Risk of Coronary Heart Disease in African Americans. Blood, 2016, 128, 11-11.	1.4	3
125	Shank2 Regulates Renal Albumin Endocytosis. Physiological Reports, 2015, 3, e12510.	1.7	10
126	Strategy and rationale for urine collection protocols employed in the NEPTUNE study. BMC Nephrology, 2015, 16, 190.	1.8	14

#	Article	IF	CITATIONS
127	HIV and chronic kidney disease. Clinical Nephrology, 2015, 83 (2015), 32-38.	0.7	69
128	Renin Lineage Cells Repopulate the Glomerular Mesangium after Injury. Journal of the American Society of Nephrology: JASN, 2015, 26, 48-54.	6.1	69
129	Replenishment of the podocyte compartment by parietal epithelial cells. Kidney International, 2015, 88, 934-935.	5.2	9
130	Circulating and urinary micro <scp>RNA</scp> profile in focal segmental glomerulosclerosis: a pilot study. European Journal of Clinical Investigation, 2015, 45, 394-404.	3.4	86
131	HIV-associated nephropathies: epidemiology, pathology, mechanisms and treatment. Nature Reviews Nephrology, 2015, 11, 150-160.	9.6	142
132	Clinical Features and Histology of Apolipoprotein L1-Associated Nephropathy in the FSGS Clinical Trial. Journal of the American Society of Nephrology: JASN, 2015, 26, 1443-1448.	6.1	104
133	APOL1 Kidney Disease Risk Variants: An Evolving Landscape. Seminars in Nephrology, 2015, 35, 222-236.	1.6	125
134	Activation of AMP-Activated Protein Kinase Prevents TGF-β1–Induced Epithelial-Mesenchymal Transition and Myofibroblast Activation. American Journal of Pathology, 2015, 185, 2168-2180.	3.8	73
135	APOL1 Risk Variants Are Strongly Associated with HIV-Associated Nephropathy in Black South Africans. Journal of the American Society of Nephrology: JASN, 2015, 26, 2882-2890.	6.1	256
136	APOL1 toxin, innate immunity, and kidney injury. Kidney International, 2015, 88, 28-34.	5.2	55
137	Sequencing rare and common APOL1 coding variants to determine kidney disease risk. Kidney International, 2015, 88, 754-763.	5.2	30
138	Preparing for Disasters for Patients on Dialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 1316-1317.	4.5	2
139	APOL1 Risk Alleles Are Associated with Exaggerated Age-Related Changes in Glomerular Number and Volume in African-American Adults. Journal of the American Society of Nephrology: JASN, 2015, 26, 3179-3189.	6.1	36
140	Innate immunity pathways regulate the nephropathy gene Apolipoprotein L1. Kidney International, 2015, 87, 332-342.	5.2	278
141	Human Immunodeficiency Virus Infection and Chronic Kidney Disease. , 2015, , 534-543.		0
142	Loss of Krüppel-like factor 6 cripples podocyte mitochondrial function. Journal of Clinical Investigation, 2015, 125, 968-971.	8.2	7
143	Copy Number Variation at the APOL1 Locus. PLoS ONE, 2015, 10, e0125410.	2.5	17
144	Association of Hemoglobin S and C Traits with Kidney Disease in African Americans in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Blood, 2015, 126, 70-70.	1.4	0

#	Article	IF	CITATIONS
145	New horizons for human pathogenic autoantibodies. Discovery Medicine, 2015, 20, 17-25.	0.5	5
146	Podocyte Injury Caused by Indoxyl Sulfate, a Uremic Toxin and Aryl-Hydrocarbon Receptor Ligand. PLoS ONE, 2014, 9, e108448.	2.5	77
147	Protective effects of aliskiren and valsartan in mice with diabetic nephropathy. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2014, 15, 384-395.	1.7	31
148	Mutations in the Gene That Encodes the F-Actin Binding Protein Anillin Cause FSGS. Journal of the American Society of Nephrology: JASN, 2014, 25, 1991-2002.	6.1	124
149	Evolution of the primate trypanolytic factor APOL1. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E2130-9.	7.1	183
150	Lipid biology of the podocyte—new perspectives offer new opportunities. Nature Reviews Nephrology, 2014, 10, 379-388.	9.6	91
151	Human podocytes perform polarized, caveolae-dependent albumin endocytosis. American Journal of Physiology - Renal Physiology, 2014, 306, F941-F951.	2.7	64
152	Enabling the genomic revolution in Africa. Science, 2014, 344, 1346-1348.	12.6	361
153	APOL1 Kidney Risk Alleles: Population Genetics and Disease Associations. Advances in Chronic Kidney Disease, 2014, 21, 426-433.	1.4	158
154	Increased mitochondrial activity in renal proximal tubule cells from young spontaneously hypertensive rats. Kidney International, 2014, 85, 561-569.	5.2	42
155	Podocytes Degrade Endocytosed Albumin Primarily in Lysosomes. PLoS ONE, 2014, 9, e99771.	2.5	39
156	PPARα and Sirt1 Mediate Erythropoietin Action in Increasing Metabolic Activity and Browning of White Adipocytes to Protect Against Obesity and Metabolic Disorders. Diabetes, 2013, 62, 4122-4131.	0.6	108
157	Erythropoietin contributes to slow oxidative muscle fiber specification via PGC-1 \hat{l} ± and AMPK activation. International Journal of Biochemistry and Cell Biology, 2013, 45, 1155-1164.	2.8	32
158	HIV-1 Vpr Induces Adipose Dysfunction in Vivo Through Reciprocal Effects on PPAR/GR Co-Regulation. Science Translational Medicine, 2013, 5, 213ra164.	12.4	60
159	Hurricane Sandy as a Kidney Failure Disaster. American Journal of Kidney Diseases, 2013, 61, 865-868.	1.9	23
160	Systemic Diagnostic Testing in Patients With Apparently Isolated Uveal Coloboma. American Journal of Ophthalmology, 2013, 156, 1159-1168.e4.	3.3	11
161	Recent Progress in the Pathophysiology and Treatment of FSGS Recurrence. American Journal of Transplantation, 2013, 13, 266-274.	4.7	97
162	miR-150 Promotes Renal Fibrosis in Lupus Nephritis by Downregulating SOCS1. Journal of the American Society of Nephrology: JASN, 2013, 24, 1073-1087.	6.1	149

#	Article	IF	CITATIONS
163	Metabolomics Reveals Signature of Mitochondrial Dysfunction in Diabetic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2013, 24, 1901-1912.	6.1	454
164	HIV-1 Vpr Enhances PPARβ/δ-Mediated Transcription, Increases PDK4 Expression, and Reduces PDC Activity. Molecular Endocrinology, 2013, 27, 1564-1576.	3.7	11
165	Renal growth in isolated methylmalonic acidemia. Genetics in Medicine, 2013, 15, 990-996.	2.4	41
166	JC viruria and kidney disease in APOL1 risk genotype individuals: is this a clue to a gene × environment interaction?. Kidney International, 2013, 84, 1069-1072.	5.2	8
167	More mechanistic insights, but translational progress is slow. Nature Reviews Nephrology, 2013, 9, 67-68.	9.6	0
168	Urinary exosomal Wilms' tumor-1 as a potential biomarker for podocyte injury. American Journal of Physiology - Renal Physiology, 2013, 305, F553-F559.	2.7	96
169	Focal segmental glomerulosclerosis is associated with a <i>PDSS2</i> haplotype and, independently, with a decreased content of coenzyme Q ₁₀ . American Journal of Physiology - Renal Physiology, 2013, 305, F1228-F1238.	2.7	36
170	Rethinking hypertensive kidney disease. Current Opinion in Nephrology and Hypertension, 2013, 22, 266-272.	2.0	65
171	Viruses and collapsing glomerulopathy: a brief critical review: TableÂ1 CKJ: Clinical Kidney Journal, 2013, 6, 1-5.	2.9	57
172	An Expanding Universe of FSGS Genes and Phenotypes. Journal of the American Society of Nephrology: JASN, 2013, 24, 1183-1185.	6.1	10
173	LMX1B is Essential for the Maintenance of Differentiated Podocytes in Adult Kidneys. Journal of the American Society of Nephrology: JASN, 2013, 24, 1830-1848.	6.1	60
174	Digital Pathology Evaluation in the Multicenter Nephrotic Syndrome Study Network (NEPTUNE). Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1449-1459.	4.5	80
175	<i>APOL1</i> Risk Variants, Race, and Progression of Chronic Kidney Disease. New England Journal of Medicine, 2013, 369, 2183-2196.	27.0	654
176	TGF-β1 stimulates mitochondrial oxidative phosphorylation and generation of reactive oxygen species in cultured mouse podocytes, mediated in part by the mTOR pathway. American Journal of Physiology - Renal Physiology, 2013, 305, F1477-F1490.	2.7	78
177	Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans. Kidney International, 2013, 83, 114-120.	5.2	210
178	Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach. Kidney International, 2013, 83, 749-756.	5.2	268
179	Tenofovir Treatment Duration Predicts Proteinuria in a Multiethnic United States Cohort of Children and Adolescents With Perinatal HIV-1 Infection. Pediatric Infectious Disease Journal, 2013, 32, 495-500.	2.0	44
180	Microalbuminuria in HIV Disease. American Journal of Nephrology, 2013, 37, 443-451.	3.1	30

#	Article	IF	CITATIONS
181	Crucial Roles of the Protein Kinases MK2 and MK3 in a Mouse Model of Glomerulonephritis. PLoS ONE, 2013, 8, e54239.	2.5	18
182	Endocytosis of Albumin by Podocytes Elicits an Inflammatory Response and Induces Apoptotic Cell Death. PLoS ONE, 2013, 8, e54817.	2.5	70
183	Glomerular Homeostasis Requires a Match between Podocyte Mass and Metabolic Load. Journal of the American Society of Nephrology: JASN, 2012, 23, 1273-1275.	6.1	6
184	Preventing renal and cardiovascular risk by renal function assessment: insights from a cross-sectional study in low-income countries and the USA. BMJ Open, 2012, 2, bmjopen-2012-001357.	1.9	32
185	HIV-associated nephropathy patients with and without apolipoprotein L1 gene variants have similar clinical and pathological characteristics. Kidney International, 2012, 82, 338-343.	5.2	57
186	Mouse models of MYH9-related disease: mutations in nonmuscle myosin II-A. Blood, 2012, 119, 238-250.	1.4	151
187	The Gne M712T Mouse as a Model for Human Glomerulopathy. American Journal of Pathology, 2012, 180, 1431-1440.	3.8	27
188	Retinoid and TGF-β Families: Crosstalk in Development, Neoplasia, Immunity, and Tissue Repair. Seminars in Nephrology, 2012, 32, 287-294.	1.6	31
189	Discovery and Fine Mapping of Serum Protein Loci through Transethnic Meta-analysis. American Journal of Human Genetics, 2012, 91, 744-753.	6.2	69
190	Genetic Risk Prediction for CKD: A Journey of a Thousand Miles. American Journal of Kidney Diseases, 2012, 59, 4-8.	1.9	1
191	Epidermal growth factor receptor promotes glomerular injury and renal failure in rapidly progressive crescentic glomerulonephritis. Nature Medicine, 2011, 17, 1242-1250.	30.7	204
192	Off the Beaten Renin–Angiotensin–Aldosterone System Pathway: New Perspectives on Antiproteinuric Therapy. Advances in Chronic Kidney Disease, 2011, 18, 300-311.	1.4	13
193	Mouse Models of Human MYH9-Related Diseases. Biophysical Journal, 2011, 100, 594a-595a.	0.5	0
194	Endogenous Retinoic Acid Activity in Principal Cells and Intercalated Cells of Mouse Collecting Duct System. PLoS ONE, 2011, 6, e16770.	2.5	17
195	Increased Prevalence of Albuminuria in HIV-Infected Adults with Diabetes. PLoS ONE, 2011, 6, e24610.	2.5	23
196	Longitudinal assessment of metabolic abnormalities in adolescents and young adults with HIV-infection acquired perinatally or in early childhood. Metabolism: Clinical and Experimental, 2011, 60, 874-880.	3.4	41
197	113 Acute Kidney Injury Secondary to Kidney Crystallization Attributable to Nelfinavir. American Journal of Kidney Diseases, 2011, 57, B45.	1.9	0
198	Chronic kidney disease worsens sepsis and sepsis-induced acute kidney injury by releasing High Mobility Group Box Protein-1. Kidney International, 2011, 80, 1198-1211.	5.2	130

#	Article	IF	CITATIONS
199	Kidney markers predict mortality in patients with HIV disease. Nature Reviews Nephrology, 2011, 7, 186-188.	9.6	3
200	TGF-beta1 reduces Wilms' tumor suppressor gene expression in podocytes. Nephrology Dialysis Transplantation, 2011, 26, 2746-2752.	0.7	24
201	APOL1 Genetic Variants in Focal Segmental Glomerulosclerosis and HIV-Associated Nephropathy. Journal of the American Society of Nephrology: JASN, 2011, 22, 2129-2137.	6.1	713
202	Pirfenidone for Diabetic Nephropathy. Journal of the American Society of Nephrology: JASN, 2011, 22, 1144-1151.	6.1	257
203	Differential Effects of MYH9 and APOL1 Risk Variants on FRMD3 Association with Diabetic ESRD in African Americans. PLoS Genetics, 2011, 7, e1002150.	3.5	81
204	Arhgap24 inactivates Rac1 in mouse podocytes, and a mutant form is associated with familial focal segmental glomerulosclerosis. Journal of Clinical Investigation, 2011, 121, 4127-4137.	8.2	234
205	Phase 1 Trial of Adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) Study Group. American Journal of Kidney Diseases, 2010, 55, 50-60.	1.9	73
206	Solid-phase synthesis and screening of N-acylated polyamine (NAPA) combinatorial libraries for protein binding. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 6500-6503.	2.2	11
207	Worldwide Distribution of the MYH9 Kidney Disease Susceptibility Alleles and Haplotypes: Evidence of Historical Selection in Africa. PLoS ONE, 2010, 5, e11474.	2.5	33
208	De novo expression of podocyte proteins in parietal epithelial cells during experimental glomerular disease. American Journal of Physiology - Renal Physiology, 2010, 298, F702-F711.	2.7	100
209	The Apolipoprotein L1 (APOL1) Gene and Nondiabetic Nephropathy in African Americans. Journal of the American Society of Nephrology: JASN, 2010, 21, 1422-1426.	6.1	242
210	African ancestry allelic variation at the MYH9 gene contributes to increased susceptibility to non-diabetic end-stage kidney disease in Hispanic Americans. Human Molecular Genetics, 2010, 19, 1816-1827.	2.9	75
211	TGF-β Signaling and the Renal Tubular Epithelial Cell: Too Much, Too Little, and Just Right. Journal of the American Society of Nephrology: JASN, 2010, 21, 1241-1243.	6.1	10
212	Adenovirus nephritis and obstructive uropathy in a renal transplant recipient: case report and literature review. CKJ: Clinical Kidney Journal, 2010, 3, 388-392.	2.9	9
213	Human Immunodeficiency Virus Infection and the Kidney. , 2010, , 675-683.		0
214	Kidneys of Alb/TGF-β ₁ Transgenic Mice Are Deficient in Retinoic Acid and Exogenous Retinoic Acid Shows Dose-Dependent Toxicity. Nephron Experimental Nephrology, 2010, 114, e127-e132.	2.2	8
215	Diabetic Nephropathy Is Accelerated by Farnesoid X Receptor Deficiency and Inhibited by Farnesoid X Receptor Activation in a Type 1 Diabetes Model. Diabetes, 2010, 59, 2916-2927.	0.6	149
216	Dense mapping of MYH9 localizes the strongest kidney disease associations to the region of introns 13 to 15. Human Molecular Genetics, 2010, 19, 1805-1815.	2.9	58

#	Article	IF	CITATIONS
217	Advanced Glycation End-Products Induce Tubular CTGF via TGF-β–Independent Smad3 Signaling. Journal of the American Society of Nephrology: JASN, 2010, 21, 249-260.	6.1	168
218	Bioenergetic characterization of mouse podocytes. American Journal of Physiology - Cell Physiology, 2010, 299, C464-C476.	4.6	123
219	Conditionally immortalized human podocyte cell lines established from urine. American Journal of Physiology - Renal Physiology, 2010, 298, F557-F567.	2.7	63
220	Cell-cell contact regulates gene expression in CDK4-transformed mouse podocytes. American Journal of Physiology - Renal Physiology, 2010, 299, F802-F809.	2.7	12
221	Proteomic analysis identifies insulin-like growth factor-binding protein-related protein-1 as a podocyte product. American Journal of Physiology - Renal Physiology, 2010, 299, F776-F784.	2.7	20
222	Trophoblast Glycoprotein: Possible Candidate Mediating Podocyte Injuries in Glomerulonephritis. American Journal of Nephrology, 2010, 32, 505-521.	3.1	5
223	Overexpression of VEGF-A in podocytes of adult mice causes glomerular disease. Kidney International, 2010, 77, 989-999.	5.2	162
224	The Non-Muscle Myosin Heavy Chain 9 Gene (MYH9) Is Not Associated with Lupus Nephritis in African Americans. American Journal of Nephrology, 2010, 32, 66-72.	3.1	18
225	Glomerular pathology in autosomal dominant MYH9 spectrum disorders: what are the clues telling us about disease mechanism?. Kidney International, 2010, 78, 130-133.	5.2	32
226	Angiotensin II overcomes strain-dependent resistance of rapid CKD progression in a new remnant kidney mouse model. Kidney International, 2010, 78, 1136-1153.	5.2	139
227	Genetics of Focal Segmental Glomerulosclerosis and Human Immunodeficiency Virus–Associated Collapsing Glomerulopathy: The Role of MYH9 Genetic Variation. Seminars in Nephrology, 2010, 30, 111-125.	1.6	30
228	MYH9 Genetic Variants Associated With Glomerular Disease: What Is the Role for Genetic Testing?. Seminars in Nephrology, 2010, 30, 409-417.	1.6	24
229	Pirfenidone: an anti-fibrotic therapy for progressive kidney disease. Expert Opinion on Investigational Drugs, 2010, 19, 275-283.	4.1	85
230	Association of Trypanolytic ApoL1 Variants with Kidney Disease in African Americans. Science, 2010, 329, 841-845.	12.6	1,725
231	Monoclonal antibodies for podocytopathies: rationale and clinical responses. Nature Reviews Nephrology, 2009, 5, 337-348.	9.6	12
232	Non-muscle myosin heavy chain 9 gene MYH9 associations in African Americans with clinically diagnosed type 2 diabetes mellitus-associated ESRD. Nephrology Dialysis Transplantation, 2009, 24, 3366-3371.	0.7	95
233	Dystroglycan in the Molecular Diagnosis of the Podocytopathies. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1696-1698.	4.5	7
234	Tetracycline-Inducible Gene Expression in Conditionally Immortalized Mouse Podocytes. American Journal of Nephrology, 2009, 29, 153-163.	3.1	19

#	Article	IF	CITATIONS
235	Fluvastatin prevents podocyte injury in a murine model of HIV-associated nephropathy. Nephrology Dialysis Transplantation, 2009, 24, 2378-2383.	0.7	21
236	Missed dialysis sessions and hospitalization in hemodialysis patients after Hurricane Katrina. Kidney International, 2009, 75, 1202-1208.	5.2	91
237	Polymorphisms in the Nonmuscle Myosin Heavy Chain 9 Gene <i>(MYH9)</i> Are Associated with Albuminuria in Hypertensive African Americans: The HyperGEN Study. American Journal of Nephrology, 2009, 29, 626-632.	3.1	71
238	Polymorphisms in the non-muscle myosin heavy chain 9 gene (MYH9) are strongly associated with end-stage renal disease historically attributed to hypertension in African Americans. Kidney International, 2009, 75, 736-745.	5.2	166
239	Phase I Trial of Rosiglitazone in FSGS. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 39-47.	4.5	34
240	Description of familial keloids in five pedigrees: evidence for autosomal dominant inheritance and phenotypic heterogeneity. BMC Dermatology, 2009, 9, 8.	2.1	53
241	Renal Gene and Protein Expression Signatures for Prediction of Kidney Disease Progression. American Journal of Pathology, 2009, 174, 2073-2085.	3.8	60
242	Advances in the biology and genetics of the podocytopathies: implications for diagnosis and therapy. Archives of Pathology and Laboratory Medicine, 2009, 133, 201-16.	2.5	49
243	Advances in the Biology and Genetics of the Podocytopathies: Implications for Diagnosis and Therapy. Archives of Pathology and Laboratory Medicine, 2009, 133, 201-216.	2.5	87
244	MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nature Genetics, 2008, 40, 1175-1184.	21.4	636
245	The Notch pathway in podocytes plays a role in the development of glomerular disease. Nature Medicine, 2008, 14, 290-298.	30.7	368
246	VEGF Inhibition and Renal Thrombotic Microangiopathy. New England Journal of Medicine, 2008, 358, 1129-1136.	27.0	1,348
247	Urinary exosomal transcription factors, a new class of biomarkers for renal disease. Kidney International, 2008, 74, 613-621.	5.2	238
248	Viruses and Kidney Disease: Beyond HIV. Seminars in Nephrology, 2008, 28, 595-607.	1.6	25
249	Lack of A1 Adenosine Receptors Augments Diabetic Hyperfiltration and Glomerular Injury. Journal of the American Society of Nephrology: JASN, 2008, 19, 722-730.	6.1	84
250	Podocytes use FcRn to clear IgG from the glomerular basement membrane. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 967-972.	7.1	233
251	Human Immunodeficiency Virus (HIV)-1 Viral Protein R Suppresses Transcriptional Activity of Peroxisome Proliferator-Activated Receptor γ and Inhibits Adipocyte Differentiation: Implications for HIV-Associated Lipodystrophy. Molecular Endocrinology, 2008, 22, 234-247.	3.7	74
252	Parvovirus-B19-associated complications in renal transplant recipients. Nature Clinical Practice Nephrology, 2007, 3, 540-550.	2.0	63

#	Article	IF	CITATIONS
253	In vitro models of TGF-β-induced fibrosis suitable for high-throughput screening of antifibrotic agents. American Journal of Physiology - Renal Physiology, 2007, 293, F631-F640.	2.7	108
254	NPHS2 Variation in Sporadic Focal Segmental Glomerulosclerosis. Journal of the American Society of Nephrology: JASN, 2007, 18, 2987-2995.	6.1	56
255	Pirfenidone Slows Renal Function Decline in Patients with Focal Segmental Clomerulosclerosis. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 906-913.	4.5	186
256	Angiotensin II provokes podocyte injury in murine model of HIV-associated nephropathy. American Journal of Physiology - Renal Physiology, 2007, 293, F1214-F1221.	2.7	28
257	Effects of transgenic expression of HIV-1 Vpr on lipid and energy metabolism in mice. American Journal of Physiology - Endocrinology and Metabolism, 2007, 292, E40-E48.	3.5	26
258	Rapid isolation of urinary exosomal biomarkers using a nanomembrane ultrafiltration concentrator. American Journal of Physiology - Renal Physiology, 2007, 292, F1657-F1661.	2.7	367
259	Kidney Patient Care in Disasters. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 814-824.	4.5	76
260	Parvovirus B19 and the Kidney: Table 1 Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, S47-S56.	4.5	105
261	Angiotensin II Type 1 Receptor Blockade Inhibits the Development and Progression of HIV-Associated Nephropathy in a Mouse Model. Journal of the American Society of Nephrology: JASN, 2007, 18, 515-527.	6.1	43
262	Kidney Patient Care in Disasters: Emergency Planning for Patients and Dialysis Facilities. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 825-838.	4.5	50
263	A Proposed Taxonomy for the Podocytopathies: A Reassessment of the Primary Nephrotic Diseases. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 529-542.	4.5	222
264	Sirolimus Therapy of Focal Segmental Clomerulosclerosis Is Associated With Nephrotoxicity. American Journal of Kidney Diseases, 2007, 49, 310-317.	1.9	63
265	Genetics of focal segmental glomerulosclerosis. Pediatric Nephrology, 2007, 22, 638-644.	1.7	33
266	NPHS2 gene, nephrotic syndrome and focal segmental glomerulosclerosis: A HuGE review. Genetics in Medicine, 2006, 8, 63-75.	2.4	83
267	Renal Bone Morphogenetic Protein-7 Protects against Diabetic Nephropathy. Journal of the American Society of Nephrology: JASN, 2006, 17, 2504-2512.	6.1	156
268	The Cyclin-Dependent Kinase Inhibitor p21 Limits Murine Mesangial Proliferative Glomerulonephritis. Nephron Experimental Nephrology, 2006, 102, e8-e18.	2.2	12
269	Kidney in viral infections. , 2006, , 275-287.		0
270	Detection and Localization of Proteinuria by Dynamic Contrast-Enhanced Magnetic Resonance Imaging Using MS325. Journal of the American Society of Nephrology: JASN, 2005, 16, 1752-1757.	6.1	13

#	Article	lF	CITATIONS
271	Squirrel Monkeys Support Replication of BK Virus More Efficiently than Simian Virus 40: an Animal Model for Human BK Virus Infection. Journal of Virology, 2005, 79, 1320-1326.	3.4	19
272	Connective Tissue Growth Factor Expressed in Tubular Epithelium Plays a Pivotal Role in Renal Fibrogenesis. Journal of the American Society of Nephrology: JASN, 2005, 16, 133-143.	6.1	170
273	Variants in the Wilms' tumor gene are associated with focal segmental glomerulosclerosis in the African American population. Physiological Genomics, 2005, 21, 212-221.	2.3	50
274	Progressive Glomerulonephritis and Histiocytic Sarcoma Associated with Macrophage Functional Defects in CYP1B1-Deficient Mice. Toxicologic Pathology, 2004, 32, 710-718.	1.8	31
275	Cultured tubule cells from TGF-β1 null mice exhibit impaired hypertrophy and fibronectin expression in high glucose. Kidney International, 2004, 65, 1191-1204.	5.2	29
276	Parapelvic kidney cysts: A distinguishing feature with high prevalence in Fabry disease. Kidney International, 2004, 66, 978-982.	5.2	41
277	Focal glomerulosclerosis in proviral and c-fms transgenic mice links Vpr expression to HIV-associated nephropathy. Virology, 2004, 322, 69-81.	2.4	58
278	Fabry disease in the era of enzyme replacement therapy: a renal perspective. Pediatric Nephrology, 2004, 19, 583-593.	1.7	15
279	HIV and the Kidney: A status report after 20 years. Current HIV/AIDS Reports, 2004, 1, 109-115.	3.1	10
280	Differential Expression of D-Type Cyclins in Podocytes in Vitro and in Vivo. American Journal of Pathology, 2004, 164, 1417-1424.	3.8	28
281	Twenty-one-year trend in ESRD due to focal segmental glomerulosclerosis in the United States. American Journal of Kidney Diseases, 2004, 44, 815-825.	1.9	230
282	Twenty-one-year trend in ESRD due to focal segmental glomerulosclerosis in the United States. American Journal of Kidney Diseases, 2004, 44, 815-25.	1.9	120
283	Mitotic cell cycle proteins increase in podocytes despite lack of proliferation. Kidney International, 2003, 63, 113-122. HIV-associated penbropathy in African Americans 11The content of this publication does not	5.2	50
284	necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. The publisher or recipient acknowledges right of the U.S. Government to retain a nonexclusive royalty-free license in and to any copyright covering the article. Kidney International	5.2	88
285	2003, 63, S43-S49. Introduction: Imperfect past, subjunctive future. Seminars in Nephrology, 2003, 23, 115-116.	1.6	1
286	Trends in the epidemiology of focal segmental glomerulosclerosis. Seminars in Nephrology, 2003, 23, 172-182.	1.6	157
287	Anti-Mouse Mesangial Cell Serum Induces Acute Glomerulonephropathy in Mice. Nephron Experimental Nephrology, 2003, 93, e92-e106.	2.2	12
288	CD2-Associated Protein Haploinsufficiency Is Linked to Glomerular Disease Susceptibility. Science, 2003, 300, 1298-1300.	12.6	435

#	Article	IF	CITATIONS
289	Hepatocyte growth factor counteracts transforming growth factor $\hat{a}\in\hat{f}^21$, through attenuation of connective tissue growth factor induction, and prevents renal fibrogenesis in 5/6 nephrectomized mice. FASEB Journal, 2003, 17, 268-270.	0.5	128
290	Fabry's Disease. New England Journal of Medicine, 2003, 349, e20.	27.0	0
291	Update in podocyte biology: putting one's best foot forward. Current Opinion in Nephrology and Hypertension, 2003, 12, 251-259.	2.0	29
292	Renal fibrosis. Frontiers in Bioscience - Landmark, 2003, 8, e68-86.	3.0	27
293	HIV-associated nephropathy in African Americans1. Kidney International, 2003, 63, 43-49.	5.2	39
294	Inducible Podocyte-Specific Gene Expression in Transgenic Mice. Journal of the American Society of Nephrology: JASN, 2003, 14, 1998-2003.	6.1	76
295	Pathogenesis and Treatment of HIV-Associated Renal Diseases: Lessons from Clinical and Animal Studies, Molecular Pathologic Correlations, and Genetic Investigations. Annals of Internal Medicine, 2003, 139, 214.	3.9	82
296	Natural History and Treatment of Renal Involvement in Fabry Disease. Journal of the American Society of Nephrology: JASN, 2002, 13, S139-S143.	6.1	97
297	Renal Pathology in Fabry Disease. Journal of the American Society of Nephrology: JASN, 2002, 13, S134-S138.	6.1	206
298	Molecular Identification of SV40 Infection in Human Subjects and Possible Association with Kidney Disease. Journal of the American Society of Nephrology: JASN, 2002, 13, 2320-2330.	6.1	123
299	Indinavirâ€Associated Interstitial Nephritis and Urothelial Inflammation: Clinical and Cytologic Findings. Clinical Infectious Diseases, 2002, 34, 1122-1128.	5.8	53
300	TGF-β1 is an Autocrine Mediator of Renal Tubular Epithelial Cell Growth and Collagen IV Production. Experimental Biology and Medicine, 2002, 227, 171-181.	2.4	36
301	BK virus and SV40 co-infection in polyomavirus nehropathy1. Transplantation, 2002, 74, 1497-1504.	1.0	110
302	Natural History of Fabry Renal Disease. Medicine (United States), 2002, 81, 122-138.	1.0	400
303	Urinary Cytology Associated With Human Polyomavirus and Indinavir Therapy in HIV-Infected Patients. American Journal of Clinical Pathology, 2002, 117, 922-926.	0.7	4
304	Nuclear Factor-l̂ºB Inhibitors as Potential Novel Anti-Inflammatory Agents for the Treatment of Immune Glomerulonephritis. American Journal of Pathology, 2002, 161, 1497-1505.	3.8	111
305	Interstitial Fibroblast-Like Cells Express Renin-Angiotensin System Components in a Fibrosing Murine Kidney. American Journal of Pathology, 2002, 160, 765-772.	3.8	29
306	Regulation of Inducible Class II MHC, Costimulatory Molecules, and Cytokine Expression in TGF-β1 Knockout Renal Epithelial Cells: Effect of Exogenous TGF-β1. Nephron Experimental Nephrology, 2002, 10, 320-331.	2.2	6

#	Article	IF	CITATIONS
307	Mice Lacking the p53-Effector Gene Gadd45a Develop a Lupus-Like Syndrome. Immunity, 2002, 16, 499-508.	14.3	170
308	Glomerular hypertrophy is associated with hyperinsulinemia and precedes overt diabetes in aging rhesus monkeys. American Journal of Kidney Diseases, 2002, 40, 1075-1085.	1.9	88
309	Modulation of podocyte phenotype in collapsing glomerulopathies. Microscopy Research and Technique, 2002, 57, 254-262.	2.2	43
310	Renal dysfunction in HIV-1-infected patients. Current Infectious Disease Reports, 2002, 4, 449-460.	3.0	15
311	BMP-7 and the proximal tubule. Kidney International, 2002, 61, 351-352.	5.2	16
312	Renal pathology in Fabry disease. Journal of the American Society of Nephrology: JASN, 2002, 13 Suppl 2, S134-8.	6.1	74
313	Natural history and treatment of renal involvement in Fabry disease. Journal of the American Society of Nephrology: JASN, 2002, 13 Suppl 2, S139-43.	6.1	39
314	Congenital nuclear cataracts and uveitis in HIV-transgenic mice. Eye, 2002, 16, 177-184.	2.1	2
315	Lsh, a SNF2 family member, is required for normal murine development. Biochimica Et Biophysica Acta - General Subjects, 2001, 1526, 211-220.	2.4	80
316	Enzyme Replacement Therapy in Fabry Disease. JAMA - Journal of the American Medical Association, 2001, 285, 2743.	7.4	1,141
317	Apoptosis in podocytes induced by TGF-β and Smad7. Journal of Clinical Investigation, 2001, 108, 807-816.	8.2	534
318	Glomerulosclerosis and viral gene expression in HIV-transgenic mice: Role of nef. Kidney International, 2000, 58, 1148-1159.	5.2	59
319	BMP receptors in kidney. Kidney International, 2000, 58, 2237-2238.	5.2	19
320	Functional and Structural Characterization of Synthetic HIV-1 Vpr That Transduces Cells, Localizes to the Nucleus, and Induces G2 Cell Cycle Arrest. Journal of Biological Chemistry, 2000, 275, 32016-32026.	3.4	102
321	Parvovirus B19 dna in kidney tissue of patients with focal segmental glomerulosclerosis. American Journal of Kidney Diseases, 2000, 35, 1166-1174.	1.9	116
322	Role of T lymphocytes in renal disease in HIV-transgenic mice. American Journal of Kidney Diseases, 2000, 35, 408-417.	1.9	7
323	Glucocorticoids suppress human immunodeficiency virus type-1 long terminal repeat activity in a cell type-specific, glucocorticoid receptor-mediated fashion: direct protective effects at variance with clinical phenomenology. Journal of Steroid Biochemistry and Molecular Biology, 2000, 75, 283-290.	2.5	33
324	Identification of Renox, an NAD(P)H oxidase in kidney. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 8010-8014.	7.1	751

#	Article	IF	CITATIONS
325	Detection of Indinavir Crystals in Urine. Archives of Pathology and Laboratory Medicine, 2000, 124, 246-250.	2.5	11
326	The HIV-1 Virion-associated Protein Vpr Is a Coactivator of the Human Glucocorticoid Receptor. Journal of Experimental Medicine, 1999, 189, 51-62.	8.5	211
327	Aging accentuates and bone marrow transplantation ameliorates metabolic defects in Fabry disease mice. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 6423-6427.	7.1	91
328	TGF-β and fibrosis. Microbes and Infection, 1999, 1, 1349-1365.	1.9	531
329	Chronic rejection of mouse kidney allografts. Kidney International, 1999, 55, 1935-1944.	5.2	57
330	lsoform specificity of commercially-available anti-TGF-β antibodies. Journal of Immunological Methods, 1999, 225, 87-93.	1.4	9
331	Glomerulosclerosis, tubulointerstitial fibrosis, and obstructive uropathy in PEPCK-TGF-β1 transgenic mice. American Journal of Kidney Diseases, 1999, 34, 177-180.	1.9	6
332	Renal Expression of Fibrotic Matrix Proteins and of Transforming Growth Factor-β (TGF-β) Isoforms in TGF-β Transgenic Mice. Journal of the American Society of Nephrology: JASN, 1999, 10, 271-280.	6.1	116
333	Hepatocyte growth factor: Mesenchymal signal for epithelial homeostasis. Kidney International, 1998, 54, 1392-1393.	5.2	27
334	Increased mortality, blunted production of nitric oxide, and increased production of TNF-α in endotoxemic TGF-β1 transgenic mice. Journal of Leukocyte Biology, 1998, 63, 31-39.	3.3	38
335	Lessons from TGF-β Transgenic Mice. Mineral and Electrolyte Metabolism, 1998, 24, 154-160.	1.1	24
336	Indinavir and Interstitial Nephritis. Annals of Internal Medicine, 1998, 128, 320.	3.9	8
337	Crystalluria and Urinary Tract Abnormalities Associated with Indinavir. Annals of Internal Medicine, 1997, 127, 119.	3.9	282
338	Cytokine regulation of schistosome-induced granuloma and fibrosis. Kidney International, 1997, 51, 1370-1375.	5.2	52
339	Renal TGF-β in HIV-associated kidney diseases. Kidney International, 1997, 51, 1568-1577.	5.2	54
340	Long-term sun exposure alters the collagen of thepapillary dermis. Journal of the American Academy of Dermatology, 1996, 34, 209-218.	1.2	202
341	Dynamics of Virus versus Host Interaction in Children with Human Immunodeficiency Virus Type 1 Infection. Journal of Infectious Diseases, 1996, 173, 1485-1490.	4.0	23
342	Induction of nephrogenic mesenchyme by osteogenic protein 1 (bone morphogenetic protein 7) Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 9021-9026.	7.1	165

#	Article	IF	CITATIONS
343	Transgenic models of HIV-1. Aids, 1995, 9, 313-324.	2.2	14
344	Transgenic models of HIV-1. Aids, 1995, 9, 313-324.	2.2	16
345	Transport of phosphorothioate oligonucleotides in kidney: Implications for molecular therapy. Kidney International, 1995, 47, 1462-1469.	5.2	124
346	Role of angiotensin II in the expression and regulation of transforming growth factor-β in obstructive nephropathy. Kidney International, 1995, 48, 1233-1246.	5.2	112
347	Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 2572-2576.	7.1	635
348	Growth Failure and AIDS-like Cachexia Syndrome in HIV-1 Transgenic Mice. Virology, 1994, 201, 147-151.	2.4	44
349	Patterns of HIV-1 mRNA Expression in Transgenic Mice Are Tissue-Dependent. Virology, 1994, 202, 940-948.	2.4	39
350	Host virus interactions and the molecular regulation of HIV-1: Role in the pathogenesis of HIV-associated nephropathy. Kidney International, 1994, 46, 16-27.	5.2	39
351	bFGF and its low affinity receptors in the pathogenesis of HIV-associated nephropathy in transgenic mice. Kidney International, 1994, 46, 759-772.	5.2	78
352	Renal vascular induction of TGF-β2 and renin by potassium depletion. Kidney International, 1993, 44, 1006-1013.	5.2	29
353	Cutaneous Disorders and Viral Gene Expression in HIV-1 Transgenic Mice. AIDS Research and Human Retroviruses, 1993, 9, 267-275.	1.1	47
354	Extracellular matrix gene expression in experimental glomerulonephritis. Current Opinion in Nephrology and Hypertension, 1993, 2, 609-617.	2.0	12
355	Sodium fluoride does not increase human bone cell proliferation or protein synthesis in vitro. Calcified Tissue International, 1992, 50, 96-97.	3.1	11
356	Renal tubular epithelial cells express osteonectin in vivo and in vitro. Kidney International, 1992, 41, 56-64.	5.2	14
357	Angiotensin II receptor-mediated proliferation of cultured human fetal mesangial cells. Kidney International, 1991, 40, 764-771.	5.2	102
358	Changes in apatite crystal size in bones of patients with osteogenesis imperfecta. Calcified Tissue International, 1991, 49, 248-250.	3.1	101
359	Sodium fluoride does not increase human bone cell proliferation or protein synthesisin vitro. Calcified Tissue International, 1990, 47, 221-229.	3.1	33
360	Journal of Bone and Mineral Research. Journal of Bone and Mineral Research, 1990, 5, S137-S141.	2.8	15

#	Article	IF	CITATIONS
361	Plasma insulin-like growth factors and bone formation in uremic hyperparathyroidism. Kidney International, 1989, 36, 471-477.	5.2	30
362	Bone Aluminum Accumulation in Hemodialysis Patients: A Longitudinal Perspective. American Journal of Kidney Diseases, 1988, 12, 214-219.	1.9	6
363	Early Deposition of Aluminum in Bone in Diabetic Patients on Hemodialysis. New England Journal of Medicine, 1987, 316, 292-296.	27.0	95
364	Bone histomorphometry of renal osteodystrophy in diabetic patients. Journal of Bone and Mineral Research, 1987, 2, 525-531.	2.8	52
365	Comparison of Parathyroid Hormone Assays with Bone Histomorphometry in Renal Osteodystrophy*. Journal of Clinical Endocrinology and Metabolism, 1986, 63, 1163-1169.	3.6	95
366	Prospective study of alcoholism treatment. American Journal of Medicine, 1983, 75, 455-463.	1.5	125
367	Infection-Related Nephropathies. , 0, , 253-262.		0